If you’re looking to add some growth to your portfolio, a great way to do it is by picking up shares of a biotech company with a recently approved product. Such a treatment will represent a brand new revenue driver for the company — and sometimes, even its first one — so if the product […]
Iovance Biotherapeutics (NASDAQ: IOVA) has been one of the hottest healthcare stocks in 2024. It has already doubled in value and investors are hopeful that there could still be more upside left for the shares now that regulators have approved one of its treatments. Does this stock have the potential to be a millionaire-making investment? […]
Iovance Biotherapeutics (NASDAQ: IOVA), one of the more high-flying biotech stocks of late, fell earthward in trading on Thursday. This was a direct consequence of its latest quarterly figures and operational update that were published after hours on Wednesday and received a fairly negative reaction from investors. The shares closed the day nearly 9% lower, […]
Shares of Iovance Biotherapeutics (NASDAQ: IOVA) had skyrocketed by 33.8% as of 10:39 a.m. ET Tuesday. The huge gain came after the company announced on Friday that the Food and Drug Administration (FDA) had granted accelerated approval for Amtagvi (lefileucel) as a treatment for advanced melanoma. Because of the Presidents’ Day holiday, the stock market […]
Iovance Biotherapeutics (NASDAQ: IOVA) has reached a major turning point in its story as a company. Later this month, the U.S. Food and Drug Administration (FDA) is set to issue a decision on what could become the company’s first commercialized product developed in house. Regulators are reviewing lifileucel for advanced melanoma, the most dangerous form […]
Shares of Iovance Biotherapeutics (NASDAQ: IOVA) popped 18.7% on Thursday as investors assessed the fallout of a clinical hold placed on a cancer-therapy trial yesterday by the U.S. Food and Drug Administration (FDA). A setback for a much-needed treatment Today’s rebound nearly recouped an almost 20% drop yesterday for Iovance, which came on the heels […]